Insights
Multiple interrelated information challenges now face the pharmaceutical and life sciences ecosystem. Agonist Health’s mission is to drive solutions to these challenges.
Looming Cost of Hand Made Drugs
Highly targeted drugs drive future growth, and their cost, utilization and complexity require new approaches
Over 50% of 2022 pharmaceutical approvals were in rare diseases or orphan conditions¹
More than half of pharmacy spend is now on specialty drugs, growing ~10% YoY²
Emerging gene therapeutics can cost over $1M annually³
Sources
² https://www.drugchannels.net/2021/12/pbms-and-drug-spending-in-2020-data.html
New Data Overload
Health data growth is unprecedented, and it outpaces efforts to organize it.
A typical phase II protocol collected 88% more data in 2015 than 2005⁴
Hospitals produce 50 PETABYTES (million gigabytes) of data annually but only use 3% effectively⁵
Genomic research will produce 2-40 EXABYTES (billion gigabytes) of data in the next decade⁶
Sources
⁵ https://www.weforum.org/agenda/2019/12/four-ways-data-is-improving-healthcare/
⁶ https://www.genome.gov/about-genomics/fact-sheets/Genomic-Data-Science
Interoperability Meets Silos
Interoperability initiatives abound, but complex legacy systems AND organizations remain bottlenecks
94% of pharma knows RWE is important
BUT LESS THAN HALF have mature RWE capabilities in place⁷
Meanwhile, only 20% of health systems trust their data
AND 51% blame interoperability challenges⁸
Sources
⁷https://www2.deloitte.com/us/en/insights/industry/health-care/real-world-evidence-study.html